Thomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.
Thomas R. Chauncey, MD, PhD
Advertisement
Articles by Thomas R. Chauncey, MD, PhD
Advertisement
Latest Updated Articles
Dr. Chauncey on Isatuximab Combinations in Multiple MyelomaDecember 1st 2021
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5